Join the Oncology Voice Network. Join for Free
Skip Level Meetings: Prepare, Purpose, Pitfalls
Skip Level Meetings Medical Science Liaison Paul Ward BeiGene Medical Affairs Xcellence Summit Momentum Events

Skip Level Meetings: Prepare, Purpose, Pitfalls


Share This Article


Summary

In this episode, Paul Ward, head of field medical at BeiGene, joins Tom Caravela to delve into the concept of skip level meetings. Paul shares insights on who should initiate these meetings and their objectives, emphasizing the importance of effective communication. The discussion covers preparation strategies for MSLs, potential benefits for leaders, and advice on avoiding common pitfalls. Paul also provides guidance on making a positive impression in informal settings and navigating group dynamics. The episode wraps up with practical advice for both MSLs and leaders, alongside a mention of Momentum Events and a discount code.

My guest today is Paul Ward, Head of Field Medical Oncology and Hematology at BeiGene and MSL Society Advisory Board Member and we discuss the pros and cons of “Skip Level” meetings.

This episode is sponsored by Momentum Events and their upcoming Medical Affairs Xcellence Summit, October 13-14 in Philadelphia. For more details, visit: https://bit.ly/3zFol58 and use discount code TOM20 to get a 20% discount on your registration! Early Bird Registration expires on August 26th.

Paul shares…

πŸ‘‰ What the term “Skip Level Meeting” means
πŸ‘‰ Who initiates these meetings
πŸ‘‰ What the goal or purpose of these meetings is
πŸ‘‰ What preparation is involved for both the leaders and the MSLs
πŸ‘‰ What positives come from these meetings
πŸ‘‰ What the dangers are that can result from these meetings
πŸ‘‰ Advice for MSLs and employees who participate in the meetings

Click for Source
Skip Level Meetings, Medical Science Liaison, Paul Ward BeiGene, Medical Affairs Xcellence Summit, Momentum Events

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN